Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab Treat and Extend for nAMD
NCT02321839Phase 4Completed
- Sponsor
- Nagoya City University
- Start
- Jan 2014
- Primary completion
- Mar 2019
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Nagoya City University. Started Jan 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02321839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321839.